Humacyte Inc.
Humacyte Inc. (HUMA): 7 pipeline candidates · ~6 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
6.4 months
D/E 8.51 · 0% dilution
Lead: Approved
7 candidates
N/A
2 buys · 2 sells (180d)
A transparent, data-derived signal for Humacyte Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$266.0M
Cash
$48.9M
Quarterly Burn
$25.1M
Runway
6.4 mo
Revenue
$495K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| acellular tissue engineered vessel | Phase 3 |
| acellular tissue engineered vessel / human acellular vessel | Phase 3 |
| atev | Phase 3 |
| biovascular pancreas | Preclinical |
| human acellular vessel | Phase 3 |
| sdatev | Phase 3 |
| symvess | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
158
Total value held
$38.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 14,316,324 | $8.7M |
| blackrock, inc. | 12,316,955 | $7.5M |
| antipodes partners ltd | 5,723,750 | $3.5M |
| great point partners llc | 3,750,000 | $2.3M |
| geode capital management, llc | 3,658,108 | $2.2M |
| state street corp | 3,043,929 | $1.8M |
| aqr capital management llc | 1,924,691 | $1.2M |
| susquehanna international group, llp | 1,757,548 | $1.1M |
| vanguard portfolio management llc | 1,417,825 | $861K |
| charles schwab investment management inc | 1,291,345 | $783K |
Showing top 10 of 158 institutional holders of Humacyte Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Humacyte Inc.'s pipeline?
Humacyte Inc. (HUMA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Humacyte Inc.'s lead drug candidate?
Humacyte Inc.'s most advanced tracked candidate is acellular tissue engineered vessel (Phase 3) for Vascular Diseases.
What is Humacyte Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Humacyte Inc. has approximately 6.4 months of cash runway.
What is Humacyte Inc.'s market capitalization?
Humacyte Inc.'s market capitalization is approximately $266.0M.
Who is the CEO of Humacyte Inc.?
Dr. Laura E. Niklason M.D., Ph.D. is the chief executive officer of Humacyte Inc. (HUMA).
Get the full picture on Humacyte Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.